Health Organization (WHO) Grade I tumor is typically seen as a well-demarcated lesion in the posterior fossa and as an infiltrating tumor in the optic pathway (OPT); it can, albeit rarely, metastasize throughout the neuraxis. Surgery is the treatment of choice for LGG and is curative if a complete resection is achieved. [11] However, when the disease is unresectable, such as when it occurs in eloquent areas or as an infiltrating tumor, other therapies such as irradiation or chemotherapy are usually used in an attempt to control disease progression. The role of these therapies in newly diagnosed patients is still undefined; no benefit has been seen with radiotherapy administered following initial partial resection rather than at the time of disease progression. [4] Unfortunately, toxicity to the pediatric brain associated with irradiation can be profound, with major long-term neurocognitive sequelae. [6] The role of chemotherapy in the treatment of LGGs has been evaluated predominantly in the pediatric population because of the desire to spare children from the toxicity of radiotherapy. A diverse spectrum of agents have been used in the treatment of LGGs in the pediatric population, including vincristine, actinomycin D, etoposide, carboplatin, carmustine, and combinations of these regimens, particularly carboplatin and vincristine. [3, 5, [7] [8] [9] [10] We previously reported a single institution experience in which carboplatin was used to treat children with progressive optic pathway glioma. [5] The success of this approach, coupled with its modest toxicity as a single agent, has led us to use carboplatin to treat both children and adults harboring progressive LGGs. We now report our experience with the first 32 patients treated in this fashion.
CLINICAL MATERIAL AND METHODS

Patient Selection and Characteristics
To be eligible for enrollment in the study, patients were required to: 1) have histological confirmation of a LGG, unless it involved the optic pathway (chiasma and optic radiations); 2) have radiographically demonstrated evidence of tumor progression (25% volume increase in the previous 3-4 months) or in case of optic pathway tumors, to have experienced progressive visual loss; and 3) have a signed informed consent form from a parent or legal guardian. Patients previously treated with chemotherapy or radiotherapy were eligible for enrollment. This study was approved by the Institutional Review Board of the participating institutions.
Thirty-two patients were enrolled in the protocol. There were 14 males and 18 females with a median age of 6.5 years (range 0.5-42 years). There were 30 patients who were younger than 14 years of age. Twenty-one patients had OPTs; 10 patients had neurofibromatosis type 1 (NF1) ( Table 1) .
Tumor histology was confirmed in 18 patients: 12 had JPAs (WHO Grade I), four had WHO Grade II gliomas, one had a pleomorphic xanthoastrocytoma (WHO Grade I), and one had an oligodendroglioma (WHO Grade II).
Previous treatment included biopsy sampling in nine patients, resection in nine patients, radiation in one patient 4 months prior to progression, and chemotherapy in three patients (8 months, 2 years, and 3 years before treatment with carboplatin).
Chemotherapy Protocol
Carboplatin (560 mg/m 2 ) was administered intravenously in 5% dextrose in one-half normal saline over a 1-hour period, preceded and followed by 1 hour of intravenous hydration (total fluid volume delivered during the 3-hour period was 900 ml/m 2 ). Carboplatin was given at 4-week intervals and continued in successive cycles until the disease progressed, unacceptable toxicity supervened, or for 12 additional cycles after achieving a maximum response. Patients with stable disease were treated with a total of 12 cycles. All patients were treated as outpatients.
Prior to instituting therapy, the following parameters were examined in each patient: complete blood cell count, serum creatinine, hepatic transaminase, and bilirubin levels. Retreatment with chemotherapy was not begun until the absolute granulocyte count was greater than 750/µl, the platelet count was greater than 100,000/µl, and the creatinine level was less than 1.5 mg/dl. Patients received a 25% dose reduction if the previous course resulted in a platelet count nadir of less than 50,000/µl. A 25% dose escalation was instituted if the prior course resulted in an absolute granulocyte count nadir of more than 1500/µl and/or a platelet count nadir of more than 100,000/µl.
Evaluation of Toxicity and Response to Therapy
Neurological and ophthalmological examinations were performed before each course of therapy was initiated. Magnetic resonance imaging was performed before therapy was started, after the initial two cycles, and then after every three cycles. After completion of treatment, magnetic resonance images were obtained every 3 months. Audiograms were performed before the first course and every 6 months thereafter. Complete blood cell counts were obtained weekly during treatment. Prior to every course, serum creatinine, hepatic transaminase, and bilirubin levels were measured. Toxicity was graded and recorded following the Pediatric Oncology Group toxicity criteria.
The response criteria were defined objectively on magnetic resonance imaging as follows: complete response (CR), complete disappearance of disease; partial response (PR), a decrease of 50% or more in tumor size; minimal response (MR), a decrease of 25% or more, but less than 50% in tumor size; stable disease (SD), no change, or less than 25% change in tumor size; and progressive disease (PD), greater than 25% increase in tumor size. Tumor size was assessed using the product of the longest measured perpendicular diameters of the enhancing component as well as the T 2 -weighted signal change of the nonenhancing component of the tumor.
RESULTS
Response to Treatment
All 32 patients received a minimum of two cycles of chemotherapy. A PR was achieved in nine patients (28%) and an MR was achieved in two (6%), for an overall response rate of 34% (11 of 32 patients). The PRs were achieved after a median of six cycles (range 4-11 cycles) and the MRs after five cycles. Four of the patients in whom a PR was achieved and one in whom an MR was achieved have now survived a median of 11.5 months after completions of therapy (range 5-13 months) and their status remains unchanged.
Eighteen patients (56%) had SD. Three are still undergoing therapy and eight completed therapy a median of 11 months ago (range 1-17 months). Five patients refused further therapy after receiving two, two, five, eight, and 10 cycles, respectively. Two patients died of respiratory complications: one of increased apnea after four cycles and one from respiratory distress of unknown cause after 10 cycles.
Tumor progression was seen in three patients after three, five, and five cycles, respectively. Patients in whom some response was achieved were among the 26 patients harboring either an OPT or a JPA, making the response rate of that group 42% (11 of 26 patients). Of the remaining six patients, there were four with SD and two with PD.
Toxicity Assessment
The 32 patients underwent a total of 387 cycles of chemotherapy. Twenty-one patients developed thrombocytopenia (platelet count < 50,000/µl), five of them did so following a 25% dose increase. Three patients needed platelet transfusions. One dose adjustment prevented further thrombocytopenia.
Nine patients developed neutropenia (absolute neutrophil count < 500/µl), one patient did so following a 25% dose increase. Only one patient developed fever with neutropenia. One dose adjustment prevented further neutropenia.
A Grade III ototoxicity occurred in one patient after five cycles of chemotherapy. One patient developed a hypersensitive reaction during the 12th and final cycle of carboplatin. No nephrotoxicity was encountered in any patient.
DISCUSSION
Low-grade gliomas form a group of tumors that are morphologically well differentiated (astrocytomas, WHO Grades I and II) but that can be clinically "malignant," infiltrating eloquent areas of the brain, acting as space-occupying lesions with mass effect, and occasionally, metastasizing. Surgical resection is the treatment of choice for localized disease with patient survival correlating with the degree of resection. [11] Unfortunately, patients with infiltrating tumors or with tumors located at crucial sites, having considerable residual disease after surgery, may derive little benefit from this therapy. The role of adjuvant therapy for residual disease is poorly defined. Therapeutic measures are difficult to assess because these tumors behave slowly, and sometimes erratically. Radiation therapy, the "standard" adjuvant therapy in adults, may bring objective responses, but may not produce an ultimate increase in patient survival. [1, 2, 12] In a recent study patients with LGGs who received radiotherapy following a subtotal resection were compared with patients who underwent radiotherapy at the time of disease progression, and the investigators found no difference in patient survival times. [4] Furthermore, pediatric patients are particularly sensitive to the neurotoxicity produced by radiotherapy, supporting efforts to defer radiotherapy for as long as possible in this population. [6] There have been previous reports in which the efficacy of chemotherapy to treat progressive LGGs in the pediatric population has been detailed. These chemotherapy regimens have included actinomycin and vincristine, [8] carboplatin, [3, 5] carboplatin and vincristine, [7] and a five-drug treatment incorporating procarbazine, 6-thioguanine, dibromodulcitol, lomustine, and vincristine. [10] The largest study to date, in which carboplatin and vincristine were administered to children with newly diagnosed progressive LGGs, was recently updated by Packer, et al. [7] This regimen produced a progression-free survival rate of 75 ± 6% at 2 years and 68 ± 7% at 3 years in 78 children, who ranged in age between 3 months and 16 years. A partial or complete response was achieved in 33% of these patients, with another 23% achieving a minimal response. These results are very encouraging and suggest that chemotherapy may well be effective in delaying radiotherapy for the majority of young children with LGG.
Our current study supplies further evidence for a role for carboplatin in the treatment of patients with progressive
LGG. The toxicity of the therapy is minimal, and, of note, the CR and PR response rate in our study is identical to that achieved with the regimen of carboplatin and vincristine used by Packer, et al. [7] Furthermore, patients harboring OPTs or JPAs had an even higher response rate of 42% compared with no response in the other six patients harboring other types of LGGs in different sites of the brain. Although few conclusions can be drawn based on the results in those six patients, there were nevertheless four patients with SD after 12 cycles of carboplatin. Two of these four patients have just completed therapy, and two continue to sustain SD, 5 and 17 months posttreatment, respectively.
Our treatment regimen involves the monthly administration of carboplatin on an outpatient basis. This may be a more practical approach because it allows the patient to avoid weekly chemotherapy. Carboplatin is not associated with the potential neurotoxic effect of vincristine. Patients participating in our study show persistent disease control following termination of chemotherapy. Disease progressed in only three patients and although two additional patients died of toxicity, it was believed to be independent of the carboplatin.
